Intuitive Surgical, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. This is an annual filing, not a standalone fourth-quarter report; selected Q4 results are included below. The company designs and sells da Vinci surgical systems, instruments and accessories, and related service and training. It reports one operating segment.
Financial and operating results
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Revenue | $2.704 billion | $2.384 billion | +13% |
| Gross profit / margin | $1.890 billion / 69.9% | $1.578 billion / 66.2% | Margin +3.7 percentage points |
| Operating income / margin | $945.2 million / 34.9% | $740.0 million / 31.0% | +28% operating income |
| Net income / diluted EPS | $735.9 million / $18.73 | $588.8 million / $15.54 | +25% net income |
| Cash from operations | $1.043 billion | $771.9 million | +$271.0 million |
| Cash, cash equivalents and investments | $4.838 billion | $3.348 billion | +$1.490 billion |
- Revenue comprised $2.187 billion of product revenue and $517.0 million of service revenue. Instruments and accessories generated $1.396 billion; systems generated $791.6 million. Recurring revenue was $1.913 billion, or 71% of total revenue.
- Approximately 753,000 procedures were performed, up about 15%; the installed base rose 9% to 3,919 systems. The company shipped 537 systems versus 492 in 2015.
- Cash from investing activities was an outflow of $1.279 billion, primarily reflecting net purchases of investments. Financing activities provided $558.5 million, including $580.9 million from employee stock plans, partly offset by repurchases and employee tax withholding.
- At year-end, current assets were $3.250 billion and current liabilities $596.5 million. Total liabilities were $709.1 million and equity $5.778 billion. The presented balance sheet does not show a debt balance or borrowing line item.
- Fourth-quarter revenue was $756.9 million, gross profit $527.2 million, net income $204.0 million, and diluted EPS $5.13. In Q4 2015, these were $676.5 million, $458.8 million, $190.0 million, and $4.99, respectively.
Material changes versus prior year
- Growth was led by recurring revenue, which increased 15%, supported by procedure growth and a larger installed base. Instrument and accessory revenue rose 17%; system revenue rose 10%.
- U.S. procedure volume increased about 13%, led by general surgery, particularly hernia repair and colorectal procedures. OUS procedures grew about 24%, slower than 26% in 2015, with urology a key contributor.
- Gross margin improved as product cost reductions and manufacturing efficiencies, product mix, and the medical-device excise-tax moratorium/refund benefited results. The 2016 product gross profit included a $7.1 million excise-tax refund benefit; 2015 included a $17.0 million excise-tax expense.
- R&D expense increased 21% to $239.6 million, reflecting broader development initiatives. SG&A increased 10% to $705.3 million, including higher international infrastructure, headcount, and legal costs.
- Effective tax rate rose to 25.0% from 22.4%. The prior-year rate benefited from a $29.3 million tax benefit related to a U.S. Tax Court opinion.
Outlook, commentary, risks and unusual items
- Management did not provide specific 2017 revenue or earnings guidance. It expected substantial continued R&D investment and planned up to $80 million more investment in strategic research, development, and clinical areas in 2017 than its typical growth rate.
- The company did not expect material revenue from its da Vinci Single Port Surgical System in 2017. A 60%-owned joint venture with Fosun Pharma, planned to develop catheter-based robotic medical devices, was expected to incur losses before commercialization and generate no revenue until after 2017; formation remained subject to regulatory approvals.
- Management cited uncertain system demand, hospital capital spending, procedure adoption and reimbursement, competition, regulatory approvals, and China import and tender authorizations. The latest Chinese authorization had expired at the end of 2015, making future placements uncertain.
- Other key risks include product liability and safety publicity, product defects or recalls, sole- and single-source suppliers, reimbursement and healthcare policy changes, foreign exchange and trade-policy exposure, and competition from established and prospective robotic-surgery entrants.
- Product liability matters included approximately 52 individual lawsuits and a separate multi-plaintiff action. The company recorded $8.3 million of 2016 charges for tolled claims and had $20.5 million accrued at year-end; it could not estimate a possible loss beyond the accrual. A securities class action and derivative actions also remained pending or subject to proposed settlement; management stated that material outcomes for several matters could not be estimated.
- After year-end, the company paid $2.0 billion under an accelerated share repurchase agreement, receiving an initial delivery of approximately 2.4 million shares; final settlement was expected by the end of Q4 2017. The medical-device excise tax moratorium covered 2016 and 2017; absent further legislative action, the tax was scheduled to resume January 1, 2018.
- The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective at December 31, 2016.
Important facts for investors to verify
- Whether procedure growth—especially U.S. general surgery and OUS urology—continues to support recurring-revenue growth and system utilization.
- Whether improved gross margins are sustainable as product mix, new-product costs, service requirements, and the excise-tax treatment change.
- Developments in China’s import authorizations and tender process, and additional Japanese procedure reimbursement approvals.
- Updates on product-liability claims, the securities class action, derivative-action settlement approval, and related insurance litigation.
- The eventual cash and share impact of the $2.0 billion accelerated repurchase, and the uses of the company’s substantial cash and investment balance.
- Progress, funding requirements, regulatory approvals, and commercialization prospects for the Fosun joint venture and other R&D programs.
- Potential effects of foreign-exchange, interest-rate, healthcare-policy, trade, and tax changes; the filing estimates a $25.2 million revenue reduction under a hypothetical 10% U.S.-dollar strengthening for 2016 exposure.